Published in Cancer Res on February 01, 2006
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene (2008) 2.19
The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol (2007) 2.07
Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets (2007) 1.44
Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife (2014) 1.44
Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents. Graefes Arch Clin Exp Ophthalmol (2012) 1.42
Inhibition of integrin-mediated crosstalk with epidermal growth factor receptor/Erk or Src signaling pathways in autophagic prostate epithelial cells induces caspase-independent death. Mol Biol Cell (2007) 1.28
Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. Clin Cancer Res (2008) 1.27
From bench to bedside: the growing use of translational research in cancer medicine. Am J Transl Res (2010) 1.22
Oncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cells. Oncogene (2006) 1.17
Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cells. Cancer Metab (2014) 0.94
Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli. J Cell Physiol (2012) 0.92
Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma. Oncotarget (2013) 0.91
RAF kinase activity regulates neuroepithelial cell proliferation and neuronal progenitor cell differentiation during early inner ear development. PLoS One (2010) 0.91
SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma. Neoplasia (2014) 0.90
Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma. Biosci Rep (2012) 0.90
Regional treatment strategies for in-transit melanoma metastasis. Surg Oncol Clin N Am (2011) 0.89
The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells. Asian J Androl (2010) 0.89
Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy. Int J Colorectal Dis (2012) 0.88
Direct Activation of Bax Protein for Cancer Therapy. Med Res Rev (2015) 0.86
ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells. Br J Pharmacol (2014) 0.86
Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. BMC Cancer (2009) 0.86
OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma. Lab Invest (2012) 0.86
Identification of novel in vivo phosphorylation sites of the human proapoptotic protein BAD: pore-forming activity of BAD is regulated by phosphorylation. J Biol Chem (2009) 0.86
Mechanisms of ferroptosis. Cell Mol Life Sci (2016) 0.84
Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling. Onco Targets Ther (2008) 0.82
BAD contributes to RAF-mediated proliferation and cooperates with B-RAF-V600E in cancer signaling. J Biol Chem (2011) 0.82
Antagonistic effect of flavonoids on NSC-741909-mediated antitumor activity via scavenging of reactive oxygen species. Eur J Pharmacol (2010) 0.82
Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells. Oncotarget (2015) 0.80
Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma. Mol Cancer (2011) 0.79
Data-derived modeling characterizes plasticity of MAPK signaling in melanoma. PLoS Comput Biol (2014) 0.79
Targeted therapies in the management of metastatic bladder cancer. Biologics (2007) 0.79
Melatonin combined with endoplasmic reticulum stress induces cell death via the PI3K/Akt/mTOR pathway in B16F10 melanoma cells. PLoS One (2014) 0.79
Novel anti-tumor mechanism of galanin receptor type 2 in head and neck squamous cell carcinoma cells. Cancer Sci (2013) 0.77
Biological evaluation of a novel sorafenib analogue, t-CUPM. Cancer Chemother Pharmacol (2014) 0.77
The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics. Biologics (2007) 0.77
Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB. Anticancer Drugs (2014) 0.76
Targeted therapy in melanoma. Biologics (2009) 0.76
Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma. Oncotarget (2016) 0.76
Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. J Cell Mol Med (2011) 0.75
Novel targeted therapies for the treatment of metastatic melanoma. Ochsner J (2010) 0.75
New advance in caspase-independent programmed cell death and its potential in cancer therapy. Int J Biomed Sci (2006) 0.75
Downregulation of amplified in breast cancer 1 contributes to the anti-tumor effects of sorafenib on human hepatocellular carcinoma. Oncotarget (2016) 0.75
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
Scalable molecular dynamics with NAMD. J Comput Chem (2005) 59.49
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
The diploid genome sequence of an Asian individual. Nature (2008) 46.29
Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet (2007) 32.41
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet (2008) 12.51
piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature (2009) 11.27
Sequencing of 50 human exomes reveals adaptation to high altitude. Science (2010) 11.27
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Management of cutaneous melanoma. N Engl J Med (2004) 9.52
Distinct epigenomic landscapes of pluripotent and lineage-committed human cells. Cell Stem Cell (2010) 8.74
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09
A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell (2004) 8.06
Automatic atom type and bond type perception in molecular mechanical calculations. J Mol Graph Model (2006) 7.93
Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. Nat Biotechnol (2009) 7.59
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 7.36
Acute renal failure and sepsis. N Engl J Med (2004) 7.18
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res (2005) 6.66
High-performance neuroprosthetic control by an individual with tetraplegia. Lancet (2012) 6.66
The dog genome: survey sequencing and comparative analysis. Science (2003) 5.84
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med (2008) 5.54
The draft genome of the transgenic tropical fruit tree papaya (Carica papaya Linnaeus). Nature (2008) 5.54
Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA (2004) 5.34
The oyster genome reveals stress adaptation and complexity of shell formation. Nature (2012) 5.30
De novo mutations in histone-modifying genes in congenital heart disease. Nature (2013) 5.15
Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med (2008) 5.14
MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res (2007) 4.95
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res (2008) 4.30
Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet (2008) 4.17
EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res (2008) 4.17
Pelvic Organ Support Study (POSST): the distribution, clinical definition, and epidemiologic condition of pelvic organ support defects. Am J Obstet Gynecol (2005) 3.85
Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet (2013) 3.83
Epigenomic analysis of multilineage differentiation of human embryonic stem cells. Cell (2013) 3.81
Epidemiological transition of stroke in China: twenty-one-year observational study from the Sino-MONICA-Beijing Project. Stroke (2008) 3.81
Natural selection on EPAS1 (HIF2alpha) associated with low hemoglobin concentration in Tibetan highlanders. Proc Natl Acad Sci U S A (2010) 3.78
Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest (2004) 3.75
Discovery and annotation of functional chromatin signatures in the human genome. PLoS Comput Biol (2009) 3.61
Residential proximity to naturally occurring asbestos and mesothelioma risk in California. Am J Respir Crit Care Med (2005) 3.55
Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11,105 pregnancies with mixed risk factors. Prenat Diagn (2012) 3.54
Surgical treatment of giant coronary artery aneurysm. J Thorac Cardiovasc Surg (2005) 3.53
ChromaSig: a probabilistic approach to finding common chromatin signatures in the human genome. PLoS Comput Biol (2008) 3.46
Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol (2009) 3.41
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A (2009) 3.39
Characteristics associated with differences in survival among black and white women with breast cancer. JAMA (2013) 3.35
Effects of acupuncture on pregnancy rates in women undergoing in vitro fertilization: a systematic review and meta-analysis. Fertil Steril (2012) 3.33
Genetic analysis of complex traits in the emerging Collaborative Cross. Genome Res (2011) 3.25
Effects of a universal classroom behavior management program in first and second grades on young adult behavioral, psychiatric, and social outcomes. Drug Alcohol Depend (2008) 3.22
Allele-specific methylation is prevalent and is contributed by CpG-SNPs in the human genome. Genome Res (2010) 3.17
Transcriptome profiling of human and murine ESCs identifies divergent paths required to maintain the stem cell state. Stem Cells (2005) 3.16
A recalibrated molecular clock and independent origins for the cholera pandemic clones. PLoS One (2008) 3.16
Effectiveness of strengthened stimulation during acupuncture for the treatment of Bell palsy: a randomized controlled trial. CMAJ (2013) 3.15
Methods for testing theory and evaluating impact in randomized field trials: intent-to-treat analyses for integrating the perspectives of person, place, and time. Drug Alcohol Depend (2008) 3.09
Quantum-sized carbon dots for bright and colorful photoluminescence. J Am Chem Soc (2006) 3.08
Adverse metabolic consequences in humans of prolonged sleep restriction combined with circadian disruption. Sci Transl Med (2012) 3.08
Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell (2011) 3.07
Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Inf Model (2010) 3.04
Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990-2010: a systematic review and analysis. Lancet (2013) 3.02
Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. Cancer Lett (2013) 2.99
The polymorphism architecture of mouse genetic resources elucidated using genome-wide resequencing data: implications for QTL discovery and systems genetics. Mamm Genome (2007) 2.82
Sleep restriction for 1 week reduces insulin sensitivity in healthy men. Diabetes (2010) 2.81
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77
NPR3 and NPR4 are receptors for the immune signal salicylic acid in plants. Nature (2012) 2.76
Autophosphorylation of the catalytic subunit of the DNA-dependent protein kinase is required for efficient end processing during DNA double-strand break repair. Mol Cell Biol (2003) 2.74
Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol (2013) 2.71
U-Pb ages from the neoproterozoic Doushantuo Formation, China. Science (2005) 2.71
Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat Cell Biol (2008) 2.68
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2004) 2.65
Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. Circulation (2012) 2.58
1-(2-Benzoyl-1-phenyl-eth-yl)-4-[(2-hy-droxy-1-naphth-yl)methyl-idene-amino]-3-methyl-1H-1,2,4-triazole-5(4H)-thione. Acta Crystallogr Sect E Struct Rep Online (2011) 2.58
Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7. Proc Natl Acad Sci U S A (2006) 2.54
Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med (2006) 2.53
Genomic ancestry of North Africans supports back-to-Africa migrations. PLoS Genet (2012) 2.51
Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell (2013) 2.50
Clinical, experimental, and genomic differences between intermediately pathogenic, highly pathogenic, and epidemic Streptococcus suis. J Infect Dis (2009) 2.49
Mesp1 coordinately regulates cardiovascular fate restriction and epithelial-mesenchymal transition in differentiating ESCs. Cell Stem Cell (2008) 2.46
Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol (2011) 2.45
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol (2012) 2.44
FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest (2012) 2.41
Calibrating the end-Permian mass extinction. Science (2011) 2.41
MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res (2009) 2.40
Regulated ATP release from astrocytes through lysosome exocytosis. Nat Cell Biol (2007) 2.38
Scavenger receptor class B type I-mediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells. Arterioscler Thromb Vasc Biol (2003) 2.38
Replanning during intensity modulated radiation therapy improved quality of life in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2012) 2.34
Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med (2011) 2.34
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
PiggyBac transposon mutagenesis: a tool for cancer gene discovery in mice. Science (2010) 2.31
Investigation of dry eye disease and analysis of the pathogenic factors in patients after cataract surgery. Cornea (2007) 2.30
Mismatch repair genes identified using genetic screens in Blm-deficient embryonic stem cells. Nature (2004) 2.29
SNVer: a statistical tool for variant calling in analysis of pooled or individual next-generation sequencing data. Nucleic Acids Res (2011) 2.27
Two key residues in ephrinB3 are critical for its use as an alternative receptor for Nipah virus. PLoS Pathog (2006) 2.26
Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol Med (2010) 2.26